Shionogi & Co Ltd - Product Pipeline Review - 2016

Published: Dec, 2016 | Pages: 88 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Shionogi & Co Ltd - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Shionogi & Co Ltd - Product Pipeline Review - 2016', provides an overview of the Shionogi & Co Ltd's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Shionogi & Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Shionogi & Co Ltd
- The report provides overview of Shionogi & Co Ltd including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Shionogi & Co Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Shionogi & Co Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Shionogi & Co Ltd's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Shionogi & Co Ltd
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Shionogi & Co Ltd's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Shionogi & Co Ltd Snapshot 9
Shionogi & Co Ltd Overview 9
Key Facts 9
Shionogi & Co Ltd - Research and Development Overview 10
Key Therapeutic Areas 10
Shionogi & Co Ltd - Pipeline Review 14
Pipeline Products by Stage of Development 14
Pipeline Products - Monotherapy 15
Pipeline Products - Combination Treatment Modalities 16
Pipeline Products - Partnered Products 17
Partnered Products/Combination Treatment Modalities 18
Pipeline Products - Out-Licensed Products 19
Out-Licensed Products/Combination Treatment Modalities 20
Shionogi & Co Ltd - Pipeline Products Glance 21
Shionogi & Co Ltd - Late Stage Pipeline Products 21
Pre-Registration Products/Combination Treatment Modalities 21
Phase III Products/Combination Treatment Modalities 22
Shionogi & Co Ltd - Clinical Stage Pipeline Products 23
Phase II Products/Combination Treatment Modalities 23
Phase I Products/Combination Treatment Modalities 24
Shionogi & Co Ltd - Early Stage Pipeline Products 25
Preclinical Products/Combination Treatment Modalities 25
Discovery Products/Combination Treatment Modalities 26
Shionogi & Co Ltd - Drug Profiles 27
A-2NTX - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
AMG-0101 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
asapiprant - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
cefiderocol - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
doripenem - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
lusutrombopag - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Monoclonal Antibody to Inhibit PcrV for Resistant Pseudomonas aeruginosa Infections - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
naldemedine tosylate - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
ospemifene - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
oxycodone hydrochloride ER - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Peptide to Agonize NPR1 and NPR2 for Non-Small Cell Lung Cancer - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
rovatirelin - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
S-010887 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
S-033188 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
S-117957 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
S-120083 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
S-222611 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
S-237648 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
S-488210 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
S-588410 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
S-600918 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
S-707106 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Small Molecule to Antagonize P2X3 Receptor for Neuropathic Pain - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Small Molecule to Block TRPV4 for Pain - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Small Molecules for Tuberculosis - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Small Molecules to Agonize CB2 for Pruritus - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Small Molecules to Antagonize NPY5R for Obesity - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Small Molecules to Inhibit Penicillin Binding Protein for Bacterial Infections - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
SR-0379 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
STAGR-120 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Shionogi & Co Ltd - Pipeline Analysis 71
Shionogi & Co Ltd - Pipeline Products by Target 71
Shionogi & Co Ltd - Pipeline Products by Route of Administration 73
Shionogi & Co Ltd - Pipeline Products by Molecule Type 74
Shionogi & Co Ltd - Pipeline Products by Mechanism of Action 75
Shionogi & Co Ltd - Dormant Projects 77
Shionogi & Co Ltd - Discontinued Pipeline Products 78
Discontinued Pipeline Product Profiles 79
ADX-415 79
capravirine 79
doripenem 79
GSK-364735 79
GW-810781 79
lisdexamfetamine dimesylate 79
lusutrombopag 80
S-234462 80
S-288310 80
S-444823 80
S-488410 80
S-5751 80
S-646240 80
S-777469 80
S-8510 81
teceleukin 81
varespladib sodium 81
velneperit 81
Shionogi & Co Ltd - Company Statement 82
Shionogi & Co Ltd - Locations And Subsidiaries 83
Head Office 83
Other Locations & Subsidiaries 83
Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 87
Disclaimer 88

List of Tables

Shionogi & Co Ltd, Key Facts 9
Shionogi & Co Ltd - Pipeline by Indication, 2016 11
Shionogi & Co Ltd - Pipeline by Stage of Development, 2016 14
Shionogi & Co Ltd - Monotherapy Products in Pipeline, 2016 15
Shionogi & Co Ltd - Combination Treatment Modalities in Pipeline, 2016 16
Shionogi & Co Ltd - Partnered Products in Pipeline, 2016 17
Shionogi & Co Ltd - Partnered Products/ Combination Treatment Modalities, 2016 18
Shionogi & Co Ltd - Out-Licensed Products in Pipeline, 2016 19
Shionogi & Co Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016 20
Shionogi & Co Ltd - Pre-Registration, 2016 21
Shionogi & Co Ltd - Phase III, 2016 22
Shionogi & Co Ltd - Phase II, 2016 23
Shionogi & Co Ltd - Phase I, 2016 24
Shionogi & Co Ltd - Preclinical, 2016 25
Shionogi & Co Ltd - Discovery, 2016 26
Shionogi & Co Ltd - Pipeline by Target, 2016 72
Shionogi & Co Ltd - Pipeline by Route of Administration, 2016 73
Shionogi & Co Ltd - Pipeline by Molecule Type, 2016 74
Shionogi & Co Ltd - Pipeline Products by Mechanism of Action, 2016 76
Shionogi & Co Ltd - Dormant Developmental Projects,2016 77
Shionogi & Co Ltd - Discontinued Pipeline Products, 2016 78
Shionogi & Co Ltd, Other Locations 83
Shionogi & Co Ltd, Subsidiaries 85